PBPK Modeler
GlaxoSmithKline
Dr. Erin Scholz, PhD, is currently a PBPK Modeler in the DMPK group at GSK. She earned her PhD in Pharmaceutical Sciences from The University of North Carolina at Chapel Hill, where her research focused on understanding heterogeneous antiretroviral distibution and HIV persistence in lymph node tissue. She has published original and review papers on her dissertation research, and has presented at several national conferences. Her current work with GSK focuses on using PBPK modeling throughout drug discovery and development to understand preliminary ADME processes, design preclinical dosing schedules, provide initial human dose predictions, evaluate DDI potential, and understand population-level differences in PK.